• About us
• Contact

Advertisement

Organisation › Details

Novo Nordisk A/S

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. *

 

	Group	Novo Group (Group)
	Industry	pharmaceutical
	Industry 2	antidiabetic
	Region	Bagsværd
	Country	Denmark
	Street	Novo Allé
	City	2880 Bagsværd
	Tel	45-4444-8888
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2021-12-13)
	Currency	DKK
	Annual sales	111,696,000,000 (sales, net, consolidated (2017) 2017-12-31)
	Profit	38,130,000 (2017-12-31)
	Cash	18,852,000,000 (2017-12-31)
		* Document for »About Section«: Novo Nordisk A/S. (12/13/21). "Press Release: Novo Nordisk Invests more than DKK 17 bn in Expansion of the Manufacturing Facilities in Kalundborg, Denmark".
		Record changed: 2024-09-21

Advertisement

More documents for Novo Group (Group)

• [1] Kivu Bioscience. (10/28/24). "Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates". San Francisco, CA....
• [2] Booster Therapeutics GmbH. (10/10/24). "Press Release: Booster Therapeutics Launches to Pioneer New Class of Proteasome Activator Medicines for the Treatment of a Range of Complex Diseases". Berlin....
• [3] Evotec SE. (9/26/24). "Press Release: Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-generation Cell Therapies". Hamburg....
• [4] NanoVation Therapeutics Inc.. (9/18/24). "Press Release: NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases". Vancouver, BC....
• [5] Asceneuron S.A.. (7/16/24). "Press Release: Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases". Lausanne & San Francisco, CA....
• [6] Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London....
• [7] Single Use Support GmbH. (5/15/24). "Press Release: Novo Holdings Acquires Majority Stake in Single Use Support". Kufstein....
• [8] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
• [9] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
• [10] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.